Clinical trials: Microvascular Disease
Diabetes Mellitus, Type 2
Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus
The trial is a phase IV clinical trial investigating the impact of Liraglutide on endothelial function and microvascular blood flow in 44 patients with type 2 diabetes mellitus aged 30-65 and HbA1c ranging from ≥ 5.5% ≤ 7.0%.
- Trial name
- NCT01208012
- Testing
- Victoza®
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- ikfe-CRO GmbH
Coronary Microvascular Disease
The Euro-CRAFT Registry
The Euro-CRAFT Registry is a prospective, multicentric, international registry of patients undergoing functional assessment of the coronary microcirculation using the continuous thermodilution technique.
- Trial name
- Euro-CRAFT (NCT05805462)
- Where
- 19 sites in Belgium, Denmark and 6 more
- Volunteers
- 671 people
- Sponsor
- CoreAalst BV
Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study
The aim of this study is to establish the diagnostic performance of the AngioAI+ System (AngioInsight, Inc, USA) for estimating: 1. Fractional flow reserve (FFR) and 2.
- Trial name
- SMARTFLOW (NCT07676097)
- Testing
- Patients with intermediate coronary artery stenosis with clinically indicated FFR assessment., Microvascular assessment
- Where
- 9 sites in United States
- Volunteers
- 620 people
- Sponsor
- AngioInsight
Angina Pectoris, Myocardial Ischemia
Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)
VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX…
- Conditions
- Angina Pectoris, Myocardial Ischemia, Heart Diseases, Cardiovascular Diseases
- Trial name
- SERRA-I US (NCT07449325)
- Testing
- A-FLUX Reducer System
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- VahatiCor, Inc.
Unstable Angina
PROTECT-TIMI 30 Trial
The primary purpose of this study was to compare the efficacy and safety of bivalirudin to eptifibatide (with or without unfractionated heparin or enoxaparin)given to subjects at high risk for heart attack and other…
- Trial name
- NCT00250471
- Testing
- Percutaneous Coronary Intervention (PCI)
- Volunteers
- 900 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Ischemic Heart Disease, Coronary Microvascular Disease
MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)
A prospective, multicenter, observational, single-arm trial to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction in patients with suspected ischemia and confirmed no…
- Conditions
- Ischemic Heart Disease, Coronary Microvascular Disease, Angina, Myocardial Ischemia
- Trial name
- MICRO2 (NCT06212466)
- Testing
- CardioFlux
- Where
- 8 sites in United States
- Volunteers
- 136 people
- Sponsor
- Genetesis Inc.
Heart Failure, Chronic Heart Failure
Wearable Tissue Oximetry During Arm Cuff Occlusion, Walking, and Standing Tests in Outpatients With Chronic Heart Failure
This prospective, single-center, observational pilot study evaluated an investigational wearable tissue oximeter (NIRSense Argus Oximetry System, also called Envello Core) in adult outpatients with chronic heart failure in New…
- Trial name
- NCT07874386
- Testing
- Argus Oximetry System
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- NIRSense Inc.
STEMI (ST Elevation MI)
Randomised EValuation of Therapies for microvAscuLar Injury in STEACS
The goal of this interventional study is to evaluate if the CoFI system can act as a platform for intracoronary infusion of therapeutic agents to treat and relieve microvascular injury in ST Elevation Acute Coronary Syndrome…
- Trial name
- REVITALISE (NCT06935383)
- Testing
- Therapeutic sequence, Diagnostic sequence
- Volunteers
- 250 people
- Sponsor
- CorFlow Therapeutics AG
Microvascular Coronary Artery Disease
A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
Primary Objective: To assess the effects of SAR407899 on coronary vasomotor function using the coronary flow reserve (CFR) in participants with microvascular angina (MVA) and/or persistent stable angina despite angiographically…
- Trial name
- NCT03236311
- Testing
- SAR407899, Adenosine, Regadenoson
- Where
- 10 sites in United States, Denmark and 3 more
- Volunteers
- 10 people
- Sponsor
- Sanofi
Microvascular Coronary Artery Disease
Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus
Primary Objective: To assess the pharmacodynamic effects of SAR247799 on macrovascular endothelial function of the brachial artery using flow-mediated dilation (FMD) in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03462017
- Testing
- SAR247799, Sildenafil, Acetylcholine
- Where
- 2 sites in Germany
- Volunteers
- 54 people
- Sponsor
- Sanofi
Angina Pectoris, Coronary Heart Disease
Evaluate the Efficacy and Safety of MUSK Pill on Coronary Microvascular Dysfunction
Objective to evaluate the effect of Shexiang Baoxin Pill on myocardial ischemia in patients with coronary microvascular dysfunction (non obstructive coronary heart disease) through a randomized, double-blind, placebo-controlled…
- Conditions
- Angina Pectoris, Coronary Heart Disease, X Syndrome, Angina, Non Obstructive Coronary Artery Disease
- Trial name
- NCT04984954
- Testing
- MUSK pill
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
Coronary Microvascular Dysfunction, Coronary Microvascular Disease
Self-Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD) (SERRA-I Study)
VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX…
- Trial name
- NCT06991322
- Testing
- A-FLUX Reducer System
- Where
- 3 sites in Netherlands, Poland and 1 more
- Volunteers
- 30 people
- Sponsor
- VahatiCor, Inc.
Non-obstructive Coronary Artery Disease
Efficacy Study of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive Coronary Artery Disease (CAD) Participants
The study is a single-center, interventional, pilot study to evaluate the improvement of microvascular function by positron emission tomography (PET) after twelve-week treatment of oral nicorandil in female non-obstructive CAD…
- Trial name
- SPET (NCT03010423)
- Testing
- Nicorandil
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
ST Elevation Myocardial Infarction
Effect of DLBS1033 After Primary PCI in Patients With STE-ACS
This is a prospective, randomized, double-blind, double-dummy, and controlled clinical study over a total of 4-week therapy with DLBS1033 in the management of STE-ACS after a primary PCI.
- Trial name
- NCT02976701
- Testing
- DLBS1033, Standard therapy
- Where
- Indonesia
- Volunteers
- 23 people
- Sponsor
- Dexa Medica Group
STEMI - ST Elevation Myocardial Infarction, Microvascular Obstruction
The MOCA I Study - Microvascular Obstruction with CoFI™ System Assessment
First-in-Human study to assess the CoFI™ device related safety and the feasibility of the diagnostic and the therapeutic sequence as well as the correlation between the dynamic microvascular resistance (dMVR) and microvascular…
- Trial name
- MOCA (NCT03654573)
- Testing
- CorFlow Controlled Flow Infusion System - CoFI™
- Where
- 8 sites in Lithuania, Switzerland and 1 more
- Volunteers
- 73 people
- Sponsor
- CorFlow Therapeutics AG
Skin Fold, Skin Laxity
A Safety and Effectiveness Study of CELLBOOSTER® Lift (Stabilized Booster Complex Using CHAC Technology)
The current post-market clinical investigation has been designed to evaluate the efficacy and safety of CELLBOOSTER® Lift, a HA-based product marketed by SUISSELLE SA.
- Conditions
- Skin Fold, Skin Laxity, Skin Texture Disorder, Skin Depression
- Trial name
- NCT06000839
- Testing
- (D0) Intradermal injection - micropapula technique, (D14) Intradermal injection - micropapula technique, (D28) Intradermal injection - micropapula technique
- Where
- France
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Suisselle
Coronary Microvascular Dysfunction
Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease
This clinical trial will explore the safety and effect of GCSF-mobilized autologous ex vivo selected CD34 cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease.
- Trial name
- NCT03508609
- Testing
- CLBS16
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Lisata Therapeutics, Inc.
Coronary Microvascular Dysfunction, Ischemic Non-Obstructive Coronary Artery Disease
MCG as a Noninvasive Diagnostic Strategy for Suspected Coronary Microvascular Dysfunction
According to the Women's Ischemic Syndrome Evaluation database, there are approximately 3 to 4 million women and men who present with signs and symptoms that are suggestive of myocardial ischemia, however they have no obstructive…
- Trial name
- MICRO (NCT05150054)
- Testing
- CardioFlux
- Where
- 4 sites in United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Genetesis Inc.
Diabetic Retinopathy
Computer-based Screening for Diabetic Retinopathy
The study is an Observational, Phase 0 designed to establish that the risk for diabetic retinopathy assigned by the RiskAnalyzer improves the reading accuracy and consistency of any reader and it decreases the inter-reader…
- Trial name
- NCT01614327
- Where
- 2 sites in United States
- Volunteers
- 19,199 people
- Sponsor
- VisionQuest Biomedical LLC
Multi Vessel Coronary Artery Disease, STEMI
Assessing Microvascular Resistance Via IMR To Predict Cumulative Outcome in STEMI Patients Undergoing Primary PCI
The purpose of this study is to assess whether the Index of Microcirculatory Resistance (IMR) can be considered a prognostic predictor for the occurrence of events at one year of follow up after primary Percutaneous Coronary…
- Trial name
- AMICRO (NCT02325973)
- Testing
- PressureWire Certus guidewire
- Where
- 14 sites in Italy
- Volunteers
- 242 people
- Sponsor
- Abbott Medical Devices